TruScreen Group (ASX:TRU, NZE:TRU) said that a July 2024 Saudi Arabia study investigating the TruScreen cervical screening technology's performance versus pap smears in cervical cancer detection was peer reviewed and published by the BMC Women's Health journal, according to bourse filings in Australia and New Zealand on Thursday.
The study tested 507 women and reported that Truscreen demonstrated a high sensitivity of 83.3%, compared to 66.7% from pap smears, and a high specificity of 95%, compared with 98.2% from pap smears, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.